Halozyme Therapeutics Appoints Herceptin® Pioneer, H. Michael Shepard, Ph.D., as Vice President of Discovery Research

Halozyme Therapeutics, Inc. (Nasdaq:HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced H. Michael Shepard, Ph.D., has joined the company as vice president, discovery research. Dr. Shepard is a recipient of numerous biotechnology patents and scientific awards for his contributions to the development of innovative therapies.

"We are delighted to have Dr. Shepard’s discovery research leadership at Halozyme,” said Gregory Frost, Ph.D., Halozyme’s chief scientific officer. "Mike’s ability to translate his broad scientific understanding into innovative biologics complements the research and development team at Halozyme as we build a world class biopharmaceutical organization.”

Dr. Shepard brings over 25 years of experience in the biotechnology industry to Halozyme. At Genentech, Dr. Shepard led the team that discovered the breast cancer drug, Herceptin (trastuzumab), which was designed to attack HER2 positive breast cancers by inhibiting their growth and enhancing their sensitivity to the immune system. In 2007, Dr. Shepard shared the Warren Alpert Prize from Harvard Medical School in recognition of this achievement. "I am excited to join Halozyme and be part of the team that will create Matrix directed therapeutics for cancer and other diseases,” said Dr. Shepard.

In addition to his accomplishments at Genentech, Dr. Shepard built successful programs at various biotechnology companies in areas as diverse as antibiotics, cancer gene therapy and receptor fusion proteins, serving as chief scientific officer of Canji, Inc. and, most recently, founder and president of Receptor BioLogix, Inc. Dr. Shepard received his bachelor’s degree in zoology from UC Davis and his Ph.D. in Molecular, Cellular and Developmental Biology from Indiana University, where he was a Damon Runyon Cancer Research Foundation Fellow.

About Halozyme Therapeutics, Inc.

Halozyme is a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the endocrinology, oncology, dermatology and drug delivery markets. The company's portfolio of products and product candidates is based on intellectual property covering the family of human enzymes known as hyaluronidases and additional enzymes that affect the extracellular matrix. Halozyme’s Enhanze^™ Technology is a novel drug delivery platform designed to increase the absorption and dispersion of biologics. The company has key partnerships with Roche to apply Enhanze Technology to Roche’s biological therapeutics for up to 13 targets and with Baxter BioScience to apply Enhanze Technology to Baxter’s biological therapeutic compound, GAMMAGARD LIQUID^™. The product candidates in Halozyme’s research pipeline target multiple areas of significant unmet medical need. For more information visit www.halozyme.com.

Safe Harbor Statement

In addition to historical information, the statements set forth above include forward-looking statements (including, without limitation, statements concerning the expected roles and responsibilities of management) that involve risk and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. The forward-looking statements are also identified through use of the words "believe," "enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict," "probable," "potential," "possible," "should," "continue," and other words of similar meaning. Actual results could differ materially from the expectations contained in forward-looking statements as a result of several factors, including regulatory approval requirements and competitive conditions. These and other factors that may result in differences are discussed in greater detail in the company's reports on Forms 10-K, 10-Q, and other filings with the Securities and Exchange Commission.